| Citation: |
BAI B, SU X, XIN H B, et al. Survival differences between endoscopic treatment and surgical treatment for patients with T1-2N0M0 duodenal neuroendocrine tumor[J]. Chin J Clin Med, 2025, 32(1): 108-113. DOI: 10.12025/j.issn.1008-6358.2025.20241120
|
To compare the long-term survival outcomes of patients with T1-2N0M0 duodenal neuroendocrine tumor (DNET) after endoscopic resection (ER) or surgical resection (SR).
Patients diagnosed with T1-2N0M0 DNET between January 1, 2004, and December 31, 2015, were extracted from the SEER database. Kaplan-Meier survival curve and log-rank test were used to compare overall survival (OS) rate and cancer-specific survival (CSS) rate between patients undergoing ER or SR. Propensity score matching (PSM) was used to reduce grouping differences, and multivariate Cox regression was used to analyze factors affecting OS and CSS before and after PSM.
A total of 656 patients were included, with 457 in ER group and 199 in SR group. Before PSM, there was no significant difference in the 5-year OS rate between the ER and SR groups (88.9% vs 89.6%), but there was a significant difference in the 5-year CSS rate (99.3% vs 96.9%, P＝0.017). Before PSM, multivariate Cox regression analysis showed advanced age was an independent risk factor for decreased OS (P＜0.001). After PSM, there was no significant difference between the ER group (n＝187) and SR group (n＝187) in 5-year OS rate (90.2% vs 88.9%) or CSS rate (98.9% vs 96.7%). After PSM, multivariate Cox regression also showed advanced age was an independent risk factor for decreased OS, while resection method was not an independent factor for OS or CSS.
There is no significant difference in OS or CSS after endoscopic treatment and surgical treatments for patients with T1-2N0M0 DNET, and advanced age is an independent factor for OS.
| [1] |
AHMED M. Gastrointestinal neuroendocrine tumors in 2020[J]. World J Gastrointest Oncol, 2020, 12(8): 791-807. DOI: 10.4251/wjgo.v12.i8.791
|
| [2] |
FITZGERALD T L, DENNIS S O, KACHARE S D, et al. Increasing incidence of duodenal neuroendocrine tumors: incidental discovery of indolent disease?[J]. Surgery, 2015, 158(2): 466-471. DOI: 10.1016/j.surg.2015.03.042
|
| [3] |
中国抗癌协会神经内分泌肿瘤专业委员会. 中国抗癌协会神经内分泌肿瘤诊治指南(2022年版)[J]. 中国癌症杂志, 2022, 32(6): 545-580.
Chinese Anti-Cancer Association Neuroendocrine Tumor Committee. China Anti-Cancer Association guideline for diagnosis and treatment of neuroendocrine neoplasm (2022 edition)[J]. China Oncol, 2022, 32(6): 545-580.
|
| [4] |
PANZUTO F, RAMAGE J, MARK PRITCHARD D, et al. European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for gastroduodenal neuroendocrine tumours (NETs) G1-G3[J]. J Neuroendocrinol, 2023, 35(8): e13306. DOI: 10.1111/jne.13306
|
| [5] |
SHAH M H, GOLDNER W S, BENSON A B, et al. Neuroendocrine and adrenal tumors, version 2.2021, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2021, 19(7): 839-868. DOI: 10.6004/jnccn.2021.0032
|
| [6] |
MEKKAN-BOUV HEZ M, DERBEY L, DE MESTIER L, et al. Survival of patients managed in France for duodenal neuroendocrine tumors (D-NET): a 20-year multicenter cohort study from the GTE group: a cohort study[J]. Int J Surg, 2024, 110(7): 4259-4265.
|
| [7] |
FOLKESTAD O, WASMUTH H H, MJØNES P, et al. Survival and disease recurrence in patients with duodenal neuroendocrine tumours—a single centre cohort[J]. Cancers (Basel), 2021, 13(16): 3985. DOI: 10.3390/cancers13163985
|
| [8] |
许 湘, 马 也, 蒋青伟, 等. 十二指肠神经内分泌肿瘤的临床特点及预后分析[J]. 临床内科杂志, 2024, 41(7): 460-463. DOI: 10.3969/j.issn.1001-9057.2024.07.006
XU X, MA Y, JIANG Q W, et al. Clinicopathological characteristics and prognosis analysis of duodenal neuroendocrine neoplasm[J]. J Clin Intern Med, 2024, 41(7): 460-463. DOI: 10.3969/j.issn.1001-9057.2024.07.006
|
| [9] |
YOON J Y, NAGULA S, KIM M K. Duodenal neuroendocrine tumors: how safe is endoscopic resection?[J]. J Gastrointest Oncol, 2024, 15(4): 2016-2018. DOI: 10.21037/jgo-24-471
|
DownLoad: